Physician profile
Peter S Young
NPI 1376543108
$4,256.99
in general payments reported to CMS, 2019-2025
32 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,891 · 2020: $285 · 2021: $415 · 2022: $498 · 2023: $746 · 2024: $152 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.95 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $923.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $541.20 | 2019-2023 | Linzess, Viberzi, Ubrelvy |
| Pfizer INC. | $352.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $291.22 | 2019-2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.37 | 2019-2023 | Synjardy, Jardiance |
| Amgen INC. | $201.64 | 2019-2023 | Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $197.73 | 2019-2021 | |
| Lilly USA, LLC | $175.11 | 2019-2023 | Mounjaro, Jardiance |
| Allergan, INC. | $163.45 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $139.05 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $132.52 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.27 | 2019-2023 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $78.41 | 2019-2023 | Trintellix |
| Esperion Therapeutics, INC. | $63.56 | 2025 | Nexletol |
| Radius Health, INC. | $61.71 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $61.50 | 2019-2023 | Ajovy |
| Novartis Pharmaceuticals Corporation | $53.84 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $52.69 | 2023 | Quviviq |
| Boston Scientific Corporation | $52.13 | 2022 | |
| Antares Pharma, INC. | $42.99 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $38.84 | 2023 | |
| Gilead Sciences, INC. | $37.98 | 2019-2020 | |
| Glaxosmithkline, LLC. | $37.57 | 2022-2023 | Shingrix |
| Daiichi Sankyo INC. | $36.50 | 2019-2020 | |
| Amarin Pharma, INC. | $26.83 | 2019 | |
| Axsome Therapeutics, INC. | $25.16 | 2023 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $23.33 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.60 | 2025 | Lifevest |
| Genentech USA, INC. | $20.23 | 2021 | |
| Abbott Laboratories | $19.55 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.63 | 2021 | |
| Endo Pharmaceuticals INC. | $14.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.